The potential rescheduling of cannabis to Schedule III has been met with a mix of celebration and skepticism within the industry. While many view this as a significant step forward, I find myself in the camp of cautious observers. As someone who has closely followed and written about cannabis policy, I’ve long maintained that Schedule III is less about progress and more about creating a sweet spot for Big Pharma to dominate the cannabis market, leaving smaller players and consumers at a disadvantage.
Germany has received nearly 900 applications for cannabis cultivation associations, but only just over half…
A Senate stopgap funding bill would delay the federal prohibition on most hemp-derived THC products…
He smokes in boardrooms, but he’s still on that underground frequency. This content originally appeared…
Fox News opinion ran a piece recently from Scott Chipman, vice president of Americans Against…
For our 50th anniversary, we handed the plant to the artists making its most striking…
Corporate valuation increased in 21 of the 38 states studied following medical marijuana legalization. Gross…